Overexpression/amplification of HER-2/neu is Uncommon in Hepatocellular Carcinoma

Overview

Journal J Clin Pathol

Specialty Pathology

Date 2005 Apr 29

PMID 15858121

Citations 20

Authors

Z-H Xian

S-H Zhang

W-M Cong

W-Q Wu

M-C Wu

Affiliations

Soon will be listed here.

Abstract

Background: Hepatocellular carcinoma (HCC) is one of the most prevalent fatal cancers in the world. Despite advances in early diagnosis and improvements in surgical techniques, the survival of patients with HCC even after resection is poor because of the high incidence of recurrences. Therefore, the identification of prognostic factors may be helpful in the development of new treatment protocols.

Aims: To investigate HER-2/neu status in HCC by immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH), and to explore the possibility of using trastuzumab in the treatment of HCC.

Methods: Eight hundred and sixty eight surgical samples from patients with primary HCC were examined for their HER-2/neu status. IHC for HER-2/neu was performed with the HercepTest kit; FISH analysis was performed with the PathVysion HER-2 DNA probe kit. The correlations between HER-2/neu overexpression and clinicopathological characteristics were analysed statistically.

Results: HER-2/neu overexpression was detected in 21 (2.42%) of the 868 primary HCCs. Only one specimen showed HER-2/neu gene amplification by FISH. No significant associations were found between HER-2/neu overexpression and the clinicopathological parameters.

Conclusions: There is a low frequency of HER-2/neu overexpression/amplification in HCC. There appears to be no role for HER-2/neu as a prognostic marker and no benefit of anti-HER-2/neu trastuzumab treatment in patients with HCC.

Citing Articles

Prognostic and Predictive Roles of HER2 Status in Non-Breast and Non-Gastroesophageal Carcinomas.

Quaquarini E, Grillo F, Gervaso L, Arpa G, Fazio N, Vanoli A Cancers (Basel). 2024; 16(18).

PMID: 39335117 PMC: 11430748. DOI: 10.3390/cancers16183145.

Mechanisms and therapeutic targets of ErbB family receptors in hepatocellular carcinoma: a narrative review.

Qiang Z, Wan J, Chen X, Wang H Transl Cancer Res. 2024; 13(6):3156-3178.

PMID: 38988928 PMC: 11231811. DOI: 10.21037/tcr-24-837.

Afatinib combined with anti-PD1 enhances immunotherapy of hepatocellular carcinoma ERBB2/STAT3/PD-L1 signaling.

Yu C, Zhang X, Wang M, Xu G, Zhao S, Feng Y Front Oncol. 2023; 13:1198118.

PMID: 37324014 PMC: 10266343. DOI: 10.3389/fonc.2023.1198118.

Prognostic Value of Erythroblastic Leukemia Viral Oncogene Homolog 2 and Neuregulin 4 in Hepatocellular Carcinoma.

Rou W, Eun H, Choung S, Jeon H, Joo J, Kang S Cancers (Basel). 2023; 15(9).

PMID: 37174100 PMC: 10177431. DOI: 10.3390/cancers15092634.

Human Epidermal Growth Factor Receptor 2 (HER2) Expression by Immunohistochemistry and Its Clinical Significance in Hepatocellular Carcinoma: A Single-Center Analysis.

Magalhaes D, Dos Santos J, Frutuoso A, Mesquita A Cureus. 2023; 15(2):e34724.

PMID: 36909127 PMC: 9997104. DOI: 10.7759/cureus.34724.

References

Baselga J, Norton L, Albanell J, Kim Y, Mendelsohn J . Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 1998; 58(13):2825-31. View

Wu M, Shen F . Progress in research of liver surgery in China. World J Gastroenterol. 2002; 6(6):773-776. PMC: 4728261. DOI: 10.3748/wjg.v6.i6.773. View

Ross J, Fletcher J, Linette G, Stec J, Clark E, Ayers M . The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist. 2003; 8(4):307-25. DOI: 10.1634/theoncologist.8-4-307. View

GOLDENBERG M . Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther. 1999; 21(2):309-18. DOI: 10.1016/S0149-2918(00)88288-0. View

Wang S, Saboorian M, Frenkel E, Hynan L, Gokaslan S, Ashfaq R . Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays. J Clin Pathol. 2000; 53(5):374-81. PMC: 1731196. DOI: 10.1136/jcp.53.5.374. View

Yaziji H, Gown A . Accuracy and precision in HER2/neu testing in breast cancer: are we there yet?. Hum Pathol. 2004; 35(2):143-6. DOI: 10.1016/j.humpath.2004.01.002. View

Nahta R, Takahashi T, Ueno N, Hung M, Esteva F . P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res. 2004; 64(11):3981-6. DOI: 10.1158/0008-5472.CAN-03-3900. View

Kay E, OGrady A, Morgan J, Wozniak S, Jasani B . Use of tissue microarray for interlaboratory validation of HER2 immunocytochemical and FISH testing. J Clin Pathol. 2004; 57(11):1140-4. PMC: 1770475. DOI: 10.1136/jcp.2003.014910. View

Menard S, Pupa S, Campiglio M, Tagliabue E . Biologic and therapeutic role of HER2 in cancer. Oncogene. 2003; 22(42):6570-8. DOI: 10.1038/sj.onc.1206779. View

10.

Ito Y, Takeda T, Sakon M, Tsujimoto M, Higashiyama S, Noda K . Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br J Cancer. 2001; 84(10):1377-83. PMC: 2363640. DOI: 10.1054/bjoc.2000.1580. View

11.

Schlieman M, Fahy B, Ramsamooj R, Beckett L, Bold R . Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. Br J Cancer. 2003; 89(11):2110-5. PMC: 2376856. DOI: 10.1038/sj.bjc.6601396. View

12.

Pietras R, Fendly B, Chazin V, Pegram M, Howell S, Slamon D . Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene. 1994; 9(7):1829-38. View

13.

Warburton C, Dragowska W, Gelmon K, Chia S, Yan H, Masin D . Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell.... Clin Cancer Res. 2004; 10(7):2512-24. DOI: 10.1158/1078-0432.ccr-03-0244. View

14.

Rhodes A, Jasani B, Anderson E, Dodson A, Balaton A . Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries. Am J Clin Pathol. 2002; 118(3):408-17. DOI: 10.1309/97WN-W6UX-XJWT-02H2. View

15.

Konecny G, Meng Y, Untch M, Wang H, Bauerfeind I, Epstein M . Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res. 2004; 10(5):1706-16. DOI: 10.1158/1078-0432.ccr-0951-3. View

16.

Collier J, Guo K, Mathew J, May F, Bennett M, Corbett I . c-erbB-2 oncogene expression in hepatocellular carcinoma and cholangiocarcinoma. J Hepatol. 1992; 14(2-3):377-80. DOI: 10.1016/0168-8278(92)90186-s. View

17.

Jacobs T, Gown A, Yaziji H, Barnes M, Schnitt S . Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol. 1999; 17(7):1983-7. DOI: 10.1200/JCO.1999.17.7.1983. View

18.

Qin L, Tang Z . The prognostic molecular markers in hepatocellular carcinoma. World J Gastroenterol. 2002; 8(3):385-92. PMC: 4656407. DOI: 10.3748/wjg.v8.i3.385. View

19.

Hsi E, Tubbs R . Guidelines for HER2 testing in the UK. J Clin Pathol. 2004; 57(3):241-2. PMC: 1770236. DOI: 10.1136/jcp.2003.009308. View

20.

Nakopoulou L, Stefanaki K, Filaktopoulos D, Giannopoulou I . C-erb-B-2 oncoprotein and epidermal growth factor receptor in human hepatocellular carcinoma: an immunohistochemical study. Histol Histopathol. 1994; 9(4):677-82. View